0

Corporate Presentation at Småbolagsdagen – September 4, 2013

Peter Wolpert, CEO and Founder

Moberg Pharma AB A DIFFERENT KIND OF PHARMA COMPANY

1

Disclaimer

1

Statements included herein that are not historical

facts are forward-looking statements. Such forward-

looking statements involve a number of risks and

uncertainties and are subject to change at any time.

In the event such risks or uncertainties materialize,

Moberg Pharma’s results could be materially

affected.

The risks and uncertainties include, but are not

limited to, risks associated with the inherent

uncertainty of pharmaceutical research and product

development, manufacturing and commercialization,

the impact of competitive products, patents, legal

challenges, government regulation and approval,

Moberg Pharma’s ability to secure new products for

commercialization and/or development and other

risks and uncertainties detailed from time to time in

Moberg Pharma’s interim or annual reports,

prospectuses or press releases.

2

2

3

3

Overview and Q2 update

Market & Products

Direct sales in the U.S.

Distributor Sales

Innovation Engine & Growth strategy

Organic and M&A

Content

4

Experienced management and board

Management

4

Anna Ljung

CFO Gustaf Lindewald Torbjörn Koivisto

Board

Peter Rothschild Peter Wolpert

CEO and Founder

Peter Wolpert

CEO and Founder Mats Pettersson

(Chair)

Wenche Rolfsen Geert Cauwenbergh George

Aitken-Davies

Steve Cagle

VP North America

Kjell Rensfeldt

VP R&D

Martin Ingman

VP Sales &

marketing, ROW

5

Share price (+24%) and trade volumes increased since

IPO May 2011

Moberg Pharma

OMXSPI

Analysts

Klas Palin, Redeye

Johan Löchen, Remium

Market Cap Sep 2, 2013

420 MSEK

5

6

Shareholders by June 30, 2013

6

Bure Equity invested 36 mkr in July (9.1%)

Strong incentives for Management and Board through Equity and Stock Options

Stock Options* to employees: Ca 6% of total shares

* Sw: Personaloptioner

Name No of shares Capital and votes, %

Östersjöstiftelsen 2 274 179 21,0

Six Sis Ag, W8imy (Bank von Roll) 1 816 510 16,8

Jpm Chase Na (Altaris Capital Partners) 825 652 7,6

Wolco Invest AB (Peter Wolpert) 600 000 5,5

Försäkringsaktiebolaget, Avanza Pension 585 305 5,4

Mobederm AB 530 341 4,9

Tredje AP-Fonden 486 000 4,5

Handelsbanken Fonder AB 468 868 4,3

7

7

Rapid growth under profitability with

Kerasal Nail/Nalox™ as key growth driver

Products based on innovative drug

delivery of proven molecules

Direct sales in the U.S.

Network of distributors/partners in RoW

Growth strategy – Organic and M&A

Moberg Pharma A DIFFERENT KIND OF PHARMA COMPANY

8

Rapid growth 2010 – 2013, SEK

8

2010 2011 2012 2013 H1

9

9

Continued strong topline growth

– Kerasal Nail™ now best selling product in its

category in the U.S.

– Majority of revenues from proprietary sales

Increased distribution

– New distribution agreements for China (Menarini)

and Mexico (Paladin)

– Additional U.S. retail chains, including Target,

Meijer and Hannaford

Platform for increased growth

– Evaluation of acquisition and in-licensing

opportunities ongoing, focus on US OTC

– Rights issue to Bure Equity (in July)

– Cash position ca 60 MSEK incl Bure issue

Second quarter highlights

10

Sales increase owing to successful acquisition and strong

organic growth

10

107% GROWTH IN

PRODUCT SALES

Q2 2012 Q2 2013

*

*Revenues Q2 2012 includes milestones of 2,8 MSEK

Net Sales, MSEK

11

Successful marketing and expanded distribution drive sales of

Nalox™/Kerasal Nail™

11

51% GROWTH IN

NALOX™/KERASAL NAIL™ PRODUCT

SALES

Q2 2012 Q2 2013

Kerasal Nail™ – U.S. market share

12

Majority of revenue from proprietary sales

12

Sales via distributors

45% Proprietary

sales 55%

JointFlex 17%

Nalox/ Kerasal Nail

69%

Kerasal 14%

RoW 8%

Europe 36%

America 54%

Channels Products Geography

Distribution of revenue, Jan - June 2013

U.S. Direct Sales - Building niche healthcare brands

14

14 Source: Retail Sales Food/Drug/Mass excluding Walmart 12 Weeks Ending July 14, 2013 as reported by IRI.

#1 #2 #10 POSITION IN THREE SELECT NICHES

® ®

Portfolio with growing

Brands

15

Efficient model for Direct Sales – platform for acquisitions

Retailers/

Wholesalers Sales Force

Contract

Manufacturers

Logistics

Sales and marketing

16

Damaged nails – an underserved market

19% expected growth in prevalence(1),

more frequent in elderly(2)

Causes embarrassing nail appearance:

– Thickened nails

– Yellow, green color

– Dry, brittle, cracked

Safety risk with oral prescription products

OTC anti fungal products cannot

penetrate the nail (as FDA requires them

to state on package)

6 – 12 months required for any results

only when the nail grows out

(1) Dermatophytic Onychomycosis – Epidemiology Forecast to 2022; EpiCast Report , March 2013

(2) Gupta, et al, 1997.

(3) IRI data, OTC packages sold in 2012, Drug, Mass and Food channels

(4) Kerasal Nail Concept Test; Persuadable Research Corporation, 2011, n = 500

30-40m AMERICANS WITH NAIL FUNGUS

1)

44% OF U.S. CONSUMERS DISSATIS-FIED WITH CURRENT OTCs

3)

5m PACKAGES SOLD IN U.S. 2012

2)

17

Available at 30 000 points of sale

Distribution added through Target,

Meijer and Hannaford

17

10% 19% market share increase last 12 months

Kerasal Nail™ – Best selling product in its category

18

Kerasal Nail now best selling product in its category in the

U.S. with 19% market share

Source, IRI: Nail fungus OTC category – Retail Dollar Sales Multi-Outlet, 4 week periods in 2012-13

Kerasal Nail Retail Sales, USD and Market share, %

0%

6%

12%

18%

24%

$0

$200 000

$400 000

$600 000

$800 000

$1 000 000

$1 200 000

$1 400 000

Kerasal Nail $ Sales Kerasal Nail % of Category Linjär (Kerasal Nail % of Category)

18

Linear

19

19

In over 15,000 stores from Sept 2013 -

- 3,800 Walmart stores

- CVS, Walgreens, and Rite Aid

Ca 30 million Americans experience

frequent foot pain1. Many simultaneously

suffer from cold feet and dry skin.

Associated with diabetes, fibromyalgia,

arthritis, joint pain, muscle strain or trauma.

Triple action formula that relieves foot pain,

warms cold feet, and moisturizes dry skin.

Active ingredients: capsaicin and camphor,

Fusome® - skin delivery system

Launch of Kerasal® NeuroCream at Walmart and major U.S.

drugstores in September 2013

1 The population prevalence of foot and ankle pain in middle and old age: a systematic review. Thomas et al, Pain 2011 Dec

Distributor Sales

21

Distributor Sales in more than 40 markets

Share of H1 Sales

No of markets sold in

Main territories

21

®

45%

EU, CANADA,

MIDDLE EAST

AND AUSTRALIA

>40

22

Continued international roll-out

Nalox™

Available in >25 markets

European growth affected by

intensifying competition, strong sales in

e.g. Nordics, France, Italy and the

Netherlands

Launch preparations at full intensity in

Canada

Distribution agreements expanded to

Mexico (Paladin) and China (Menarini)

Preparations for Chinese market

approval will begin shortly

Note: Not an all inclusive list.

22

Innovation Engine

24

24

Organic growth

Current products growing, line extensions

Launches in new markets

8 patent families enable additional products

- MOB-015

- Non-clinical programs >100 NEW BUSINESS OPPORTUNITIES TO BE EVALUTED 2013

Acquisitions/inlicensing

Products

- Focus on US OTC market

- Nordics: OTC, Derma and Women’s Health

Drug Delivery technologies

- Topical/semisolids

25

MOB 015 generates high TBF concentrations in nail

Phase II trial ongoing (fully recruited in May 2013)

25

Target profile for MOB-015

Low Medium High

High

Medium

Low

Efficacy

Existing

tablets MOB-015

Nalox™

Existing

topicals

Safety

Source: Hui, Maibach et al, Drug Development and Industrial Pharmacy, 2012; Franz cell experiments with human nail;

Amount TBF in the deeper part of the nail plate

** Schatz F, et al; Clin Exp Dermatol, 1995 Sep;20(5):377-83

Terbinafine concentration in human nail, µg/g nail

0,5

> 613

Oral terbinafine therapy** MOB-015*

Building a different kind of pharma company

27

27

Building A DIFFERENT KIND OF PHARMA COMPANY

Continued strong product demand – Kerasal® Nail™

now top selling U.S. product in its category

Expanded distribution in the U.S.

Majority of revenues from proprietary sales

Larger geographical reach – new agreements for

China and Mexico

Continuous evaluation of acquisition and in-licensing

opportunities

- US OTC products

- Nordic products

- Drug Delivery